Dividends Inside 
Kyntra Bio, Inc.
KYNB
$7.05 (+ $0.01 + 0.14%)
Last updated: 2026-08-15 03:21 UTC
Kyntra Bio, Inc. trades under ticker KYNB on NASDAQ as a stock. Use this page to review stock price, share price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US31572Q8814, CUSIP 31572Q881. Also searched as Kyntra Bio.
Related researchKYNB stock priceKYNB share price31572Q881Kyntra Bio stockKyntra Bio share price
About the Company
Kyntra Bio, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for serious unmet medical needs. Kyntra Bio’s current pipeline centers on oncology and anemia, including FG-3246, an antibody-drug conjugate targeting CD46 for metastatic castration-resistant prostate cancer and other cancers, as well as roxadustat, a small-molecule HIF-PH inhibitor being developed for anemia-related indications. The company also works in fibrotic disease biology through its research on hypoxia-inducible factor and connective tissue growth factor pathways. Headquartered in San Francisco, California, Kyntra Bio serves the broader life sciences market by advancing treatments intended for patients with cancer, blood disorders, and other severe diseases.
Price History
Latest News for KYNB
Kyntra Bio Inc (KYNB) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic Advances ...
Kyntra Bio Inc (KYNB) reports increased revenue and improved cost management, while advancing key clinical trials and maintaining a strong cash position.
Kyntra Bio (KYNB) Q1 2026 Earnings Transcript
Gaia Vasiliver-Shamis: Good afternoon, everyone, and thank you for joining us today to discuss Kyntra Bio, Inc.’s first quarter 2026 financial and business results. Joining me on today’s call are Thane Wettig, chief executive officer, David DeLucia, chief financial officer, and Carol Gaddum, vice president of product development. Such statements may include, but are not limited to, collaborations with AstraZeneca and Astellas, financial guidance, the initiation, enrollment, design, conduct, and results of clinical trials, regulatory strategies and potential regulatory results, research and development activities, commercial results, and results of operations, risks related to our business, and certain other business matters.
Kyntra Bio (KYNB) Reports Q1 Loss, Tops Revenue Estimates
Kyntra Bio (KYNB) delivered earnings and revenue surprises of -11.48% and +140.39%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update
Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is progressing well with the interim analysis anticipated in 4Q 2026 Positive results from the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC were presented at ASCO GU in February 2026, further validating key Phase 2 monotherapy design elements Pivotal Phase 3 trial protocol of ro
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Beats Revenue Estimates
Beam Therapeutics (BEAM) delivered earnings and revenue surprises of -4.60% and +52.44%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Kyntra Bio to Report First Quarter 2026 Financial Results
SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce first quarter 2026 financial results on Monday, May 11 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationKyntra Bio management team will host a conference call and webcast presentation to discuss the financial resu